Long Circulation Red‐Blood‐Cell‐Mimetic Nanoparticles with Peptide‐Enhanced Tumor Penetration for Simultaneously Inhibiting Growth and Lung Metastasis of Breast Cancer

Su, Jinghan; Sun, Hongwei; Meng, Qingshu; Yin, Qi; Tang, Shan; Zhang, Pengcheng; Chen, Yi; Zhang, Zhiwen; Li, Yaping

doi:10.1002/adfm.201504780

Cited by 197 publications

(132 citation statements)

References 50 publications

Supporting

Mentioning

126

Contrasting

Order By: Relevance

“…Thus, DOX-containing dendritic conjugate were in favor of treating cancer cells with no damage to hearts. It is well known that 4T1 cells easily metastasize to lung and liver [51]. As confirmed by H&E staining, the metastatic foci were clearly seen in lung and liver in both saline and free DOX treated groups (Fig.…”

Section: Histopathological Analysesmentioning

confidence: 62%

Enzyme/pH-sensitive dendritic polymer-DOX conjugate for cancer treatment

et al. 2018

View full text Add to dashboard Cite

It is in a great demand to design a biodegradable, tumor microenvironment-sensitive drug delivery system to achieve safe and highly efficacious treatment of cancer. Herein, a novel pH/enzyme sensitive dendritic pdiHPMA-DOX conjugate was designed. diHPMA dendritic copolymer with GFLG segments in the branches which are sensitive to the intracellular enzyme of the tumor was prepared through RAFT polymerization. DOX was attached to dendritic diHP-MA polymer through a pH-sensitive hydrazone bond. The dendritic pdiHPMA-DOX conjugate self-assembled into nanoparticles with an ideal spherical shape at a mean size of 103 nm. The DOX attached to the polymeric carrier was released in an acidic environment, and the GFLG linker for synthesizing the dendritic vehicle with a high molecular weight (M W , 220 kDa) was cleaved to release low M W segments (<40 kDa) in the presence of cathepsin B. The dendritic polymeric conjugate was internalized via an endocytic pathway, and then released the anticancer drug, which led to significant cytotoxicity for tumors. The blood circulation time was profoundly prolonged, resulting in high accumulation of DOX into tumors. In vivo anti-tumor experiments with 4T1 tumor bearing mice demonstrated that the conjugate had a better antitumor efficacy in comparison with free DOX. Additionally, body weight measurements and histological examinations indicated that the conjugate showed low toxicities to normal tissues. This dendritic polymeric drug carrier in a response to intracellular enzyme and acidic pH of tumor tissue or cells holds great promise in tumor-targeted therapy.

show abstract

Section: Histopathological Analysesmentioning

confidence: 62%

Enzyme/pH-sensitive dendritic polymer-DOX conjugate for cancer treatment

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Histological examination results also exhibited no obvious damage to the major organs after treating with Rq/PTX, which were mainly filled with abundant cells ( Figure 7E). All these experimental results indicated that Rq/PTX had low systemic toxicity and was more biocompatible than Taxol, and implicated that the presence of Rq could lead to the accumulation of PTX in vivo, 59 further resulting in the suppression of tumor growth.…”

mentioning

confidence: 85%

Noncovalent interaction-assisted drug delivery system with highly efficient uptake and release of paclitaxel for anticancer therapy

Wei

Zhang

et al. 2017

IJN

View full text Add to dashboard Cite

An effective drug delivery system requires efficient drug uptake and release inside cancer cells. Here, we report a novel drug delivery system, in which paclitaxel (PTX) interacts with a novel cell penetrating peptide (CPP) through noncovalent interaction designed based on molecular simulations. This CPP/PTX complex confers high efficiency in delivering PTX into cancer cells not by endocytosis but by an energy-independent pathway. Once inside cells, the noncovalent interaction between PTX and the CPP may allow fast release of PTX within cells due to the direct translocation of CPP/PTX. This drug delivery system exhibits strong capacity for inhibition of tumor growth and offers a new avenue for the development of advanced drug delivery systems for anticancer therapy.

show abstract

“…[116] Li et al recently developed cell membrane coated PTX-loaded PCL nanoparticles for the treatment of metastatic breast cancer. [117, 118] In these nanoparticles, PCL served as reservoir for PTX, while the cell membranes endowed the nanomedicine with camouflage properties such as long circulation and tumor targeting. Increased accumulation in both primary tumor and their metastasis sites was achieved, leading to greatly improved efficacy, again when compared to Taxol ® .…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy

Wang

Porter

Konstantopoulos

et al. 2017

Journal of Controlled Release

Self Cite

136

View full text Add to dashboard Cite

Paclitaxel (PTX) is one of the most successful drugs ever used in cancer chemotherapy, acting against a variety of cancer types. Formulating PTX with Cremophor EL and ethanol (Taxol®) realized its clinical potential, but the formulation falls short of expectations due to side effects such as peripheral neuropathy, hypotension, and hypersensitivity. Abraxane®, the albumin bound PTX, represents a superior replacement of Taxol® that mitigates the side effects associated with Cremophor EL. While Abraxane® is now considered a gold standard in chemotherapy, its 21% response rate leaves much room for further improvement. The quest for safer and more effective cancer treatments has led to the development of a plethora of innovative PTX formulations, many of which are currently undergoing clinical trials. In this context, we review recent development of PTX drug delivery systems and analyze the design principles underpinning each delivery strategy. We chose several representative examples to highlight the opportunities and challenges of polymeric systems, lipid-based formulations, as well as prodrug strategies.

show abstract

Long Circulation Red‐Blood‐Cell‐Mimetic Nanoparticles with Peptide‐Enhanced Tumor Penetration for Simultaneously Inhibiting Growth and Lung Metastasis of Breast Cancer

Cited by 197 publications

References 50 publications

Enzyme/pH-sensitive dendritic polymer-DOX conjugate for cancer treatment

Enzyme/pH-sensitive dendritic polymer-DOX conjugate for cancer treatment

Noncovalent interaction-assisted drug delivery system with highly efficient uptake and release of paclitaxel for anticancer therapy

Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy

Contact Info

Product

Resources

About